Search research articles
Contact Us
Filters
Showing results (31-40 of 99) with videos related to
Page
of 10
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2013
Specialized pathology review in patients with ovarian cancer: results from a prospective study
Stefan Kommoss, Jacobus Pfisterer, Alexander Reuss, et al.
Annals of Surgical Oncology
|
February 19, 2010
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
Pauline Wimberger, Michael Wehling, Nils Lehmann, et al.
Gynecologic Oncology
|
March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years
Thorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
Gynecologic Oncology
|
May 19, 2009
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Werner Meier, Andreas du Bois, Alexander Reuss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2015
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Jalid Sehouli, Christina Fotopoulou, Edibe Erol, et al.
Gynecologic Oncology
|
January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Jacek P Grabowski, Philipp Harter, Florian Heitz, et al.
Gynecologic Oncology
|
December 13, 2006
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Uwe Wagner, Andreas du Bois, Jacobus Pfisterer, et al.
Histopathology
|
September 17, 2013
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review
Stefan Kommoss, Cyril Blake Gilks, Friedrich Kommoss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma
Jonathan A Ledermann, Daniela Luvero, Aaron Shafer, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 99) with videos related to
Sort By:
Page
of 10
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 22, 2013
Specialized pathology review in patients with ovarian cancer: results from a prospective study
Stefan Kommoss, Jacobus Pfisterer, Alexander Reuss, et al.
Annals of Surgical Oncology
|
February 19, 2010
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
Pauline Wimberger, Michael Wehling, Nils Lehmann, et al.
Gynecologic Oncology
|
March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years
Thorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
Gynecologic Oncology
|
May 19, 2009
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Werner Meier, Andreas du Bois, Alexander Reuss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2015
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Jalid Sehouli, Christina Fotopoulou, Edibe Erol, et al.
Gynecologic Oncology
|
January 26, 2016
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Jacek P Grabowski, Philipp Harter, Florian Heitz, et al.
Gynecologic Oncology
|
December 13, 2006
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Uwe Wagner, Andreas du Bois, Jacobus Pfisterer, et al.
Histopathology
|
September 17, 2013
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review
Stefan Kommoss, Cyril Blake Gilks, Friedrich Kommoss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma
Jonathan A Ledermann, Daniela Luvero, Aaron Shafer, et al.
Page
of 10